How to Help Your Patients Save Money on Symbravo: A Provider's Guide to Savings Programs

Symbravo (meloxicam 20 mg / rizatriptan 10 mg) is a clinically meaningful advancement in acute migraine therapy — but at approximately $1,300–$1,420 for 9 tablets, the cost burden is significant and can prevent patients from filling the prescription at all. Prescription abandonment is a preventable outcome when providers take proactive steps at the point of care. This guide covers every cost-reduction mechanism available for Symbravo in 2026, giving your team a complete toolkit to support patient access.

Understanding the Symbravo Cost Landscape

Symbravo's cost challenges stem from three compounding factors:

Brand-name only: Approved January 2025, no generic will be available for years

Limited insurance coverage: Most Medicare Part D plans don't cover it; commercial plans require PA; Medicaid requires PA

High retail price: ~$1,382–$1,420 for 9 tablets cash; ~$1,110–$1,143 with GoodRx

Given these barriers, the default patient experience without proactive provider intervention is: pharmacy rejection → sticker shock → abandonment. Each of the strategies below addresses one or more of these barriers.

Strategy 1: Enroll Commercially Insured Patients in the On My Side Savings Program

The Symbravo On My Side Savings Program from Axsome Therapeutics is the most impactful tool available for commercially insured patients. Eligible patients can pay as little as $10 for up to a 90-day supply of Symbravo. Program details:

Enrollment: Call 866-496-2976 or through the Axsome patient support portal

Eligibility: Commercial (private) insurance required. NOT valid for Medicare, Medicaid, TRICARE, or other federal/state health programs

Copay accumulator/maximizer note: Patients whose plans use accumulator programs may not have savings card payments count toward their deductible. Advise these patients accordingly.

Office workflow recommendation: Add a savings program handout or savings card to every Symbravo prescription's discharge packet. Your front desk staff should ask "What type of insurance do you have?" at checkout to identify eligible patients before they go to the pharmacy.

Strategy 2: Submit Prior Authorization at Time of Prescribing

For commercial and Medicaid patients, most plans require prior authorization for Symbravo — and some require step therapy (documenting failure of at least one or two triptans). Submitting the PA at prescribing rather than waiting for a pharmacy reject eliminates days of delay. When building your PA documentation, include:

Complete documentation of prior acute migraine treatments: drug name, dose, duration, outcome (failure, intolerance, inadequate response)

Objective migraine burden: MIDAS score ≥11 or HIT-6 ≥56 significantly strengthens a medical necessity argument

Clinical rationale for dual-mechanism therapy: reference MOMENTUM (inadequate prior acute therapy response) or EMERGE (inadequate gepant response) trial data

Functional impact: documented effect on work, family, or quality of life (e.g., ER visits, missed workdays, disability)

Strategy 3: Appeal Denials Proactively

First-level PA denials are common for newer branded medications and should not be the end of the road. Key steps:

Request a peer-to-peer review: Allows your clinical team to speak directly with the insurance medical reviewer to make a physician-to-physician clinical case

Submit a formal appeal with updated documentation: Include clinical studies (MOMENTUM, EMERGE), headache society guidelines, and individualized patient notes

Request formulary exception: If Symbravo is not on the formulary, a formulary exception request can place it on the plan's covered drug list for this patient

Strategy 4: Samples to Bridge Coverage Gaps

Physician samples provide immediate therapeutic access while PA processes are pending or appeals are underway. Contact your Axsome Therapeutics sales representative to establish a sample supply. Document sample provision in the patient record per your standard practice. For migraine patients who need Symbravo acutely, samples can be the difference between treated and untreated attacks during an administrative delay.

Strategy 5: Discount Cards for Medicare and Medicaid Patients

Medicare and Medicaid patients are excluded from the manufacturer savings program. For these patients, GoodRx or SingleCare discount cards provide modest savings on the cash price (~17–20% off). These can be used if:

Medicare Part D doesn't cover Symbravo (which is currently the case for most plans)

The GoodRx cash price is lower than the insurance copay (compare before dispensing)

Remind patients that they cannot use GoodRx and insurance simultaneously — they choose whichever is lower.

Strategy 6: Patient Assistance Programs for Uninsured Patients

Uninsured patients who can't afford Symbravo may qualify for a patient assistance program (PAP). Contact Axsome Therapeutics at 1-800-484-1672 or direct patients to NeedyMeds.org or RxAssist.org to identify available programs. PAP eligibility typically requires proof of income and uninsured status, and the application process takes time — so start early when possible.

Strategy 7: When to Consider a Cost-Effective Alternative

For patients who cannot access Symbravo despite all available support programs, a cost-effective alternative may be the pragmatic choice. The closest therapeutic alternative is generic Treximet (sumatriptan/naproxen sodium) — also a triptan/NSAID combination — available at a significantly lower cost. Generic triptans alone (generic rizatriptan, generic sumatriptan) are widely available for under $30–50/month at most pharmacies. Gepants (Ubrelvy, Nurtec ODT) may be better covered by some plans, particularly for patients with cardiovascular contraindications to triptans.

Provider Checklist: Symbravo Cost Management

Confirm insurance type at appointment (commercial, Medicare, Medicaid, uninsured)

Submit prior authorization simultaneously with Symbravo prescription for plans that require it

Give commercially insured patients the savings program card/number (866-496-2976) before they go to pharmacy

Provide samples to bridge the gap while PA is pending

For Medicare/Medicaid patients excluded from savings program: recommend GoodRx or SingleCare discount cards

Appeal all PA denials — request peer-to-peer review with insurance medical director

Have a cost-effective backup prescription ready (generic Treximet or generic triptan) for patients who cannot access Symbravo

For patients who have their savings sorted but still need help locating Symbravo at a pharmacy, recommend medfinder for providers — which calls pharmacies near the patient to find which ones have the medication in stock, texting results directly to the patient.